Arch Biopartners (ARCH) AI Stock Analysis

• Market Cap: C$48.86M
• Dividend Yield: N/A
• Average Volume (3M): 43.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: N/A
• EPS Growth: 10.49%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 66,933,290
• 10 Day Avg. Volume: 31,059
• 30 Day Avg. Volume: 43,967
• PEG Ratio: 0.88
• Price to Book (P/B): -21.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -53.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.16
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.76 ▼(-44.23% Downside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is primarily held down by weak financial performance (no TTM revenue, persistent losses, negative equity, and ongoing cash burn). Technical indicators also point to a bearish trend with weak momentum. Valuation does not provide support due to negative earnings and no dividend yield data.

Positive Factors

Focused DPEP-1 inhibitor platform

A concentrated platform focus (DPEP-1/LSALT Peptide) creates durable technical depth and repeatable R&D pathways across inflammatory indications. This reduces program dispersion, supports efficient resource allocation, and enhances appeal for long-term partnerships and licensing opportunities.

Monoclonal antibody program for organ injury

A complementary monoclonal antibody program targeting extracellular histones broadens the therapeutic portfolio and indication coverage. Structural diversification across modalities increases the firm's strategic optionality for collaborations, risk-sharing with partners, and multiple potential value-creating exit pathways.

Partnership/licensing-centric business model

An explicit partnership/out-licensing model is a durable commercialization path for clinical-stage biotech: it allows capital-efficient development, milestone and royalty revenue potential, and risk transfer to larger pharma, preserving upside while limiting required in-house commercialization spend.

Negative Factors

No TTM revenue and ongoing net losses

Zero trailing revenue and repeated net losses mean the company cannot self-fund development and must rely on external capital or deals. Over the medium term this increases dilution risk, constrains strategic choices, and limits bargaining power with potential partners or acquirers.

Persistent negative operating and free cash flow

Consistent negative operating and free cash flow point to ongoing cash burn that will require financing to sustain clinical programs. This creates execution risk for trials and program timelines, increases the frequency of dilution events, and pressures management to secure deals quickly.

Thin balance sheet and material debt

Negative equity, small reported assets and material debt indicate elevated solvency and refinancing risk. Limited financial flexibility can hamper R&D continuity, reduce runway between financings, and weaken negotiating leverage in partner discussions or any restructuring scenarios.

Arch Biopartners Business Overview & Revenue Model

Company Description

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.

How the Company Makes Money

Arch Biopartners primarily generates revenue through the development and commercialization of its drug candidates. The company invests in the research and development of its proprietary technologies, aiming to bring them to market either independently or through strategic partnerships with larger pharmaceutical companies. Revenue streams include potential licensing agreements, milestone payments, and royalties from successful commercialization of its drug candidates. Additionally, Arch Biopartners may receive government grants or research funding to support its development efforts, particularly for projects addressing unmet medical needs.

Arch Biopartners Financial Statement Overview

Summary

Financial strength is very weak: TTM revenue is $0, net losses persist (TTM about -$2.7M), operating/free cash flow are negative (TTM about -$1.5M), and stockholders’ equity is negative (TTM about -$3.6M). The thin asset base and ongoing burn imply continued reliance on external funding.

Income Statement

Profitability is weak and inconsistent. TTM (Trailing-Twelve-Months) revenue is $0 with a net loss of about $2.7M, following multiple years of losses (annual net income roughly -$1.2M to -$3.9M). Revenue has been volatile (strong growth in 2023 vs. 2022, modest growth in 2024), and margins have generally been deeply negative, indicating the business is still heavily in investment/burn mode with limited near-term earnings visibility.

Balance Sheet

Balance sheet risk is elevated. Stockholders’ equity is negative in every period shown (TTM about -$3.6M), which limits financial flexibility and increases reliance on external funding. Debt remains material (TTM about $2.6M; higher in prior years), and total assets are very small in TTM ($25K), highlighting a thin capital base relative to ongoing losses.

Cash Flow

Cash generation is weak, with persistent cash burn. TTM (Trailing-Twelve-Months) operating cash flow is about -$1.5M and free cash flow is also about -$1.5M, and free cash flow growth is negative in TTM. While annual cash burn has fluctuated (notably much lower in 2023 vs. 2021/2024), the overall pattern remains consistently negative, implying continued funding needs absent a step-change in revenue or cost structure.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	2.12M	1.98M	964.68K	3.89M
Gross Profit	0.00	-1.66M	-129.00K	-503.00K	-150.00K
EBITDA	-1.29M	-3.53M	-336.00K	-101.00K	-77.02K
Net Income	-1.55M	-3.92M	-3.33M	-1.41M	-1.17M
Balance Sheet
Total Assets	104.53K	935.62K	1.17M	621.64K	2.67M
Cash, Cash Equivalents and Short-Term Investments	2.10K	2.97K	831.27K	506.35K	448.24K
Total Debt	2.84M	2.77M	5.02M	4.41M	5.16M
Total Liabilities	3.99M	5.28M	6.68M	5.09M	6.55M
Stockholders Equity	-3.88M	-4.35M	-5.51M	-4.47M	-3.88M
Cash Flow
Free Cash Flow	-1.58M	-2.33M	-234.08K	-1.08M	-2.98M
Operating Cash Flow	-1.58M	-2.33M	-234.07K	-1.08M	-2.98M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	1.58M	1.50M	559.00K	-421.37K	2.78M

Arch Biopartners Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Negative. The current price of 1.37 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 1.05, and above the 200-day MA of 1.36, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 30.32 is Neutral, neither overbought nor oversold. The STOCH value of 16.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ARCH.

Arch Biopartners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MSCL	46 Neutral	C$178.55M	-5.03	-89.10%	―	―	27.53%
BCT	46 Neutral	C$41.55M	-0.41	-409.25%	―	―	62.01%
MDNA	42 Neutral	C$54.98M	-4.40	-91.21%	―	―	54.74%
ARCH	41 Neutral	C$48.86M	-12.93	―	―	―	10.49%